Bottom line
Semaglutide (Ozempic / Wegovy) and tirzepatide (Mounjaro / Zepbound) are the two most prescribed GLP-1 molecules in the world. Until recently, the comparison relied on cross-trial inference — comparing the STEP program for semaglutide against the SURMOUNT program for tirzepatide, with all the caveats that come with different patient populations, endpoints, and comparators.
That changed with SURMOUNT-5, the first head-to-head randomized trial directly comparing semaglutide 2.4 mg/week against tirzepatide at its maximum tolerated dose (up to 15 mg/week) for weight management. The results were clear:
- Tirzepatide produced greater total body weight loss — roughly
20.2% vs 13.7% at 72 weeks, a difference of about 47% more weight loss in relative terms.
- More tirzepatide patients reached ≥15% and ≥20% weight loss
thresholds.
- Side effect profiles were similar — GI events (nausea,
diarrhea, constipation) were the most common in both arms.
That doesn't mean tirzepatide is universally "better." The right molecule for a given patient depends on indication, insurance, tolerability, and cardiovascular goals. Here's how to think through it.
The molecules
Semaglutide is a single-agonist GLP-1 receptor agonist. It binds the GLP-1 receptor in the gut, pancreas, and brain, producing:
- Reduced appetite via hypothalamic signaling
- Slower gastric emptying
- Enhanced glucose-dependent insulin secretion
- Reduced glucagon in the hyperglycemic state
Approved as Ozempic for type 2 diabetes (up to 2 mg/week) and as Wegovy for chronic weight management (2.4 mg/week). Also available as Rybelsus (oral, diabetes only) and as Wegovy pill (oral, weight management, approved 2026).
Tirzepatide is a dual GLP-1 / GIP receptor agonist. It does everything semaglutide does at the GLP-1 receptor, plus activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP activation appears to independently enhance fat metabolism and may contribute to the additional weight loss observed versus semaglutide.
Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea, both up to 15 mg/week.
What SURMOUNT-5 actually showed
SURMOUNT-5 enrolled adults with BMI ≥30 (or ≥27 with a comorbidity) without type 2 diabetes. Patients were randomized to either tirzepatide (titrated to maximum tolerated dose, up to 15 mg) or semaglutide 2.4 mg, for 72 weeks. Primary endpoint: percent change in body weight.
Key results:
Weight loss:
- Tirzepatide arm: −20.2% mean body weight loss
- Semaglutide arm: −13.7% mean body weight loss
- Difference: −6.5 percentage points (statistically significant)
Threshold analysis:
- ≥5% weight loss: 96% tirzepatide vs 86% semaglutide
- ≥10% weight loss: 83% tirzepatide vs 65% semaglutide
- ≥15% weight loss: 67% tirzepatide vs 42% semaglutide
- ≥20% weight loss: 50% tirzepatide vs 23% semaglutide
- ≥25% weight loss: 31% tirzepatide vs 10% semaglutide
Side effects:
- GI events (nausea, diarrhea, constipation, vomiting): similar
rates, roughly 70-80% cumulative in both arms
- Discontinuation due to adverse events: similar (~6-8%)
- No new safety signals in either arm
What the trial did not measure:
- Cardiovascular outcomes (that's SELECT, semaglutide-only so far)
- Diabetes-specific outcomes (these patients didn't have diabetes)
- Long-term (>72 week) outcomes
- Body composition (lean mass vs fat mass)
- Quality of life as a primary endpoint
Where semaglutide has the edge
Despite losing the weight-loss race, semaglutide has three significant advantages in 2026:
1. Cardiovascular outcome data. The SELECT trial (semaglutide 2.4 mg vs placebo in patients with established cardiovascular disease and obesity) showed a 20% reduction in major adverse cardiovascular events (MACE). Wegovy is now FDA-approved specifically for reducing cardiovascular risk in this population. Tirzepatide does not yet have a completed cardiovascular outcome trial — SURPASS-CVOT is ongoing but results are not expected until 2027 or later.
For patients with established heart disease, this is a major differentiator. A cardiologist in 2026 has strong trial evidence to prescribe Wegovy. They do not yet have equivalent evidence for Zepbound.
2. Broader insurance coverage. Semaglutide has been on the market longer (Ozempic since 2017, Wegovy since 2021 vs Mounjaro in 2022, Zepbound in 2023). More plans have it on formulary, more prior-authorization pathways are established, and more prescribers are experienced with it.
3. Oral option. Rybelsus (oral semaglutide for diabetes) has been available since 2019. The Wegovy pill (oral semaglutide for weight management) was approved in 2026. There is no oral tirzepatide option yet. For patients who won't inject, semaglutide is the only weekly GLP-1 option in oral form.
Where tirzepatide has the edge
1. More weight loss. SURMOUNT-5 settles this. At maximum doses, tirzepatide produces meaningfully more weight loss than semaglutide. For patients whose primary goal is maximum weight reduction — and who are not constrained by the factors above — tirzepatide is the stronger molecule.
2. Better glucose control in diabetes. The SURPASS-2 trial (tirzepatide vs semaglutide 1 mg for type 2 diabetes) showed significantly greater HbA1c reductions with tirzepatide. For patients with type 2 diabetes, tirzepatide provides stronger glycemic control.
3. Lower cash pricing via LillyDirect. Eli Lilly's direct-to-consumer channel offers Zepbound at roughly $349–549/month for self-pay patients. NovoCare's Wegovy pricing is $499–649/month. The gap is real for cash-paying patients.
[program:lillydirect]
4. Sleep apnea indication. Zepbound has an FDA-approved indication for obstructive sleep apnea in adults with obesity. Wegovy does not. For patients where OSA is a primary concern, Zepbound has the regulatory backing.
Tolerability differences
In practice, some patients tolerate one molecule better than the other, even at equivalent dose intensities. Patterns prescribers commonly observe:
- Nausea: roughly similar rates, but some patients who couldn't
tolerate semaglutide do well on tirzepatide (or vice versa). The mechanisms are related but not identical.
- Constipation: slightly more common with tirzepatide in some
studies.
- Injection site reactions: both rare. Tirzepatide occasionally
produces more localized reactions, but this is uncommon.
- Fatigue: reported in both; some patients report less fatigue
after switching from semaglutide to tirzepatide.
If you've had intolerable side effects on one molecule, a switch to the other is standard practice before concluding that GLP-1 therapy doesn't work for you. See our guide on how to switch.
How to decide
A simplified framework:
Start with tirzepatide if:
- Maximum weight loss is the primary goal
- You have type 2 diabetes and need aggressive glucose control
- You're self-pay and cost matters (LillyDirect pricing)
- You have obstructive sleep apnea as a primary diagnosis
- You've tried semaglutide and couldn't tolerate it
Start with semaglutide if:
- You have established cardiovascular disease (SELECT data)
- Your insurance covers Wegovy/Ozempic but not Zepbound/Mounjaro
- You want an oral option (Wegovy pill or Rybelsus)
- You've tried tirzepatide and couldn't tolerate it
Neither molecule is wrong for most patients. The difference in weight loss (6.5 percentage points) is meaningful but both drugs produce substantial results. A patient who loses 14% of their body weight on semaglutide has achieved a clinically significant outcome.
What about switching mid-treatment?
Common scenario: a patient is on semaglutide and wants to switch to tirzepatide for greater weight loss, or vice versa for insurance reasons.
Switching is clinically straightforward:
- No washout period is needed
- Dose equivalence is approximate — there's no published
bioequivalence crosswalk, but most prescribers start tirzepatide at 5 mg when switching from semaglutide 1-2.4 mg
- GI side effects may recur during the first few weeks on the
new molecule
- Insurance prior authorization will need to be resubmitted
See our full guide on switching GLP-1 drugs.
The bigger picture
Semaglutide and tirzepatide are both first-generation drugs in what will be a large and increasingly differentiated class. Retatrutide (triple agonist, GLP-1/GIP/glucagon) is in Phase 3 with even larger weight-loss numbers. Orforglipron (oral non-peptide GLP-1) was approved in 2026 with a different convenience profile. Amycretin (dual amylin/GLP-1) is in development with promising early data.
The question of "which GLP-1 is best" will only get more nuanced as the class expands. For now, semaglutide and tirzepatide are the two options with the deepest clinical evidence and the widest availability. Choosing between them is a real decision that should be made with your prescriber based on your specific clinical picture, insurance situation, and treatment goals — not on social media hype.